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Antibiotic Therapy in Preventing Exacerbations of Severe Chronic Obstructive 
Pulmonary Disease
Jamie Trautner PA-S
Department of Physician Assistant Studies, University of North Dakota School of Medicine & Health Sciences
Grand Forks, ND  58202-9037
Abstract
Introduction
• COPD is a chronic, slowly developing progressive 
disease.  Symptoms include shortness of breath, 
wheezing, coughing and frequent respiratory infections.
• Standard pharmacological treatment includes inhaled 
bronchodilators and corticosteroids (National Heart, Lung, 
and Blood Institute [NHIBI], 2017). 
• In severe cases, would adding a macrolide antibiotic to 
their standard treatment decrease exacerbations and 
improve overall health and quality of life?  Do the benefits 
of antibiotic therapy outweigh the risks?
• In an effort to answer the above questions, the chosen 
studies and review articles included adults (18 years and 
older), having a history of moderate to very severe COPD, 
having had one to three acute exacerbations of COPD 
(AECOPD) in the last year and continuing on standard 
therapy for COPD. 
Research Question
Literature Review




• Current research indicates there is significant 
improvement in symptom exacerbation for the patients 
using long-term antibiotic therapy.
• Is standard pharmacological therapy enough to 
prevent exacerbations?
• Kew, Mavergames and Walters (2013) found that LABAs 
are effective for moderate/severe COPD.  However, 
mainly Caucasian males were used in their research.
• Is there a benefit to adding long-term antibiotics?
• Seemungal et al. (2014) found a significant reduction in 
exacerbations for erythromycin versus placebo (35%) 
(p=0.006).  However, the study only had 109 patients.
• Sethi et al. (2010) showed Moxifloxacin given for five days 
a week reduced exacerbations by 25% and those with 
mucopurulent sputum had a reduction of 45%.
• What are the risks of long-term antibiotics?
• Chronic or long-term use of antibiotics will always bring 
up a concern for bacterial resistance. 
• Albert et al. (2011) found that patients using long-term 
azithromycin showed more resistance to macrolides in 
respiratory pathogens compared to placebo.  However, 
Simoens et al. (2013) found no difference in macrolide 
resistance (azithromycin 52% and placebo 57%)(p=0.64)
• Ray and colleagues (2012) showed an increase in 
cardiovascular and all-cause mortality with azithromycin 
versus placebo.
• As discussed, the data is proving the benefit, but it needs 
to be used in an appropriate patient population.  With all 
patients involved in this therapy, bacterial resistance is the 
main risk and concern. 
• Chronic obstructive pulmonary disease (COPD) is a 
progressive disease that has no cure but is treatable.  
The treatment goal is to have adequate symptom control, 
decreased exacerbations, prevent hospitalizations and 
maintain an independent quality of life.   
• The review of literature is to determine if the benefits of 
long-term antimicrobial therapy outweigh the risks in the 
treatment of severe COPD.
• The gold standard for pharmacotherapy consists of 
inhaled corticosteroids and bronchodilators (long-acting 
beta2 agonist (LABA).  
• Adding azithromycin to standard therapy for patients with 
frequent exacerbations showed a 27% reduction in 
exacerbation frequency.  
• With prolonged use of antimicrobials there is an 
increased risk of bacterial resistance.  However, in doing 
this research, it was found that bacterial resistance was 
not noticed between azithromycin (52%) versus placebo 
(57%), p = 0.64.  
• Although long-term antimicrobial therapy is becoming a 
hot topic, it is imperative that we continue to study the 
detrimental development of bacterial resistance.  
1. In patients with severe COPD, are standard 
pharmacological methods of therapy enough to prevent 
exacerbations?
2. In patients with severe COPD, what are the benefits of 
adding a long-term macrolide antibiotic to standard 
therapy?
3. In patients with severe COPD, what are the risks and 
contraindications of adding a long-term macrolide 
antibiotic to standard therapy?
• The literature yielded high-quality studies concerning 
macrolide antibiotics and their effects, benefits, and 
challenges in preventing and treating AECOPD.
• An Overview of COPD - COPD is the third leading cause 
of death in the United States (U.S.).  In determining the 
severity of a patient's COPD, the clinician will classify 
them in a stage based on their pulmonary function tests 
(PFT) and symptoms.
• GOLD Stages (Lung Institute, 2016)
• The Benefits of Macrolide Antibiotics in Preventing 
and Treating COPD Exacerbations – An exacerbation is 
defined as an increase in respiratory symptoms over 
baseline that usually requires a change in therapy 
(Miravitlles, 2010).
• Miravitlles (2010) found that bacterial eradication 
decreases the inflammatory nature of the airways in turn 
helping reduce exacerbations.
• In one study by Seemungal, Wilkinson, Hurst, Perera, 
Sapsford, & Wedzicha (2014), erythromycin 250 mg twice 
daily showed a 35% reduction in exacerbations.
• The Risks of Macrolide Antibiotics in Preventing and 
Treating COPD Exacerbations - Antibiotic resistance is 
a major public health problem world-wide and an 
international effort is needed to counteract its emergence.
• In a study by Albert et al. (2011) the percentage of 
resistance to macrolides in respiratory pathogens isolated 
from nasopharyngeal swabs was greatly increased in the 
azithromycin population compared to the placebo arm. 
• In a very large cohort of Tennessee Medicaid patients, 
Ray and colleagues (2012) demonstrated increased 
cardiovascular and all-cause mortality during azithromycin 
therapy compared to placebo.
• Long-term antibiotic use for the prevention and treatment 
of AECOPD is being minimally used at this point.
• In discussing this topic with Val Tomhave, RRT and 
supervisor of the Sanford Pulmonary Rehab, she states 
that three of her patients with severe to very severe COPD 
are currently using long-term azithromycin therapy with 
great success.
• The majority of COPD patients (up to two thirds) are non-
exacerbators, therefore, not candidates for long-term 
antibiotics.
• Patients suffering from frequent or severe infective 
exacerbations despite optimal pharmacological and non-
pharmacological treatment would be candidates for long-
term antibiotic treatment.
• Primary care providers will inevitably play a pivotal role in 
the use of this therapy.
• Due to the large push for preventative medicine, primary 
care will be a major factor by helping patients with 
smoking cessation, eating a healthy diet, getting regular 
cardiovascular exercise and overcoming psychosocial 
barriers to accomplish a healthy lifestyle.  
• I would like to thank Val Tomhave, RRT, Professor 
Marilyn Klug, PhD, and my peer group for their valuable 
input in helping me develop this project.  I especially want 
to thank my wife, Angie, my children Aubrie and Kaylee 
for the continued encouragement, support and motivation 
to accomplish something I didn't think would be possible!
Statement of the Problem
• Patients with severe COPD that have exhausted all 
modalities of standard treatment, may still suffer from 
"flare ups" or exacerbations of symptoms which can alter 
their quality of life and lead to frequent hospitalizations 
(NHIBI, 2017). 
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Stage One Mild COPD with FEV1 about 80 percent or more of normal.  COPD commonly causes slight airflow limitations.
Stage Two Moderate COPD with FEV1 between 50 and 80 percent of normal.  Usually during this stage, most people seek help for 
COPD symptoms of coughing, wheezing and shortness of breath.
Stage Three Severe COPD with FEV1 between 30 and 50 percent of normal.  Typically, in this stage, COPD symptoms worsen, 
causing decreased quality of life.
Stage Four Very severe COPD with a lower FEV1 than stage three, or those with stage three FEV1 and low blood oxygen levels.  
Generally, this stage is known as end stage COPD, meaning the disease has progressed, lung function has deteriorated 
and flare-ups could be life threatening.
